Treatment of severe aplastic anemia and hematopoietic stem cell transplantation
10.3969/j.issn.1674-7445.2023.03.017
- VernacularTitle:重型再生障碍性贫血的治疗与造血干细胞移植
- Author:
Yanjuan LI
1
;
Liansheng ZHANG
;
Lijuan LI
Author Information
1. Department of Hematology, Lanzhou University Second Hospital, the Second Clinical Medical College of Lanzhou University, Lanzhou 730000, China
- Publication Type:Research Article
- Keywords:
Severe aplastic anemia;
Immunosuppressive therapy;
Allogeneic hematopoietic stem cell transplantation;
Haploidentical hematopoietic stem cell transplantation;
Umbilical cord blood transplantation;
Antithymocyte globulin;
Eltrombopag;
Sirolimus;
Alemtuzumab;
Cyclophosphamide
- From:
Organ Transplantation
2023;14(3):442-
- CountryChina
- Language:Chinese
-
Abstract:
Severe aplastic anemia (SAA) is a severe bone marrow failure syndrome caused by multiple causes, which is clinically manifested with severe anemia, infection and bleeding. The complex pathogenesis of SAA has not been fully understood. SAA is characterized with acute onset, severe disease condition and rapid progression. At present, with the in-depth study of SAA and the improvement of diagnosis and treatment, the therapeutic strategy for SAA has been evolved from classical immunosuppressive therapy based on antithymocyte globulin and cyclosporine to the application of thrombopoietin receptor agonist and combined treatment based on allogeneic hematopoietic stem cell transplantation, which may promote the reconstruction of hematopoietic function of SAA patients to varying degree and significantly improve survival and clinical prognosis, becoming the research hotspot of SAA treatment. In this article, new advances in the treatment of SAA at home and abroad were reviewed.
